Approved for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 in individuals 9 months through 55 years of age. Contains capsular polysaccharides from four meningococcal serogroups (A, C, Y, W-135) conjugated to diphtheria toxoid protein. Conjugation enhances immunogenicity and produces long-lasting… Side effects, costs, interactions,…
Loading full data from Know Your Drugs Institute…